I now have excellent source material. I have everything I need to craft a powerful, clinician-grade introduction and conclusion for a seminar on the Van den Bergh test, anchored in this clinical case. Let me write this.
SEMINAR: THE VAN DEN BERGH TEST FOR BILIRUBIN
INTRODUCTION
A 22-hour-old baby. Fully formed. Three kilograms. Born through an elective caesarean section in a booked, uneventful pregnancy. By all accounts, a healthy start to life.
By the 15th hour - he was yellow.
Not mildly jaundiced. Not physiologically yellow. Kramer zone 5. Every inch of him stained with bilirubin. His serum bilirubin clocked 25 mg/dL before the day was done. Over the next 72 hours, he would require not one, not two, but four exchange transfusions. His haemoglobin fell. His temperature rose. The differential grew crowded - ABO incompatibility, G6PD deficiency, neonatal sepsis. A family history of jaundice in all three older siblings. A mother with blood group O. A father with blood group B. A baby who inherited the worst of both.
This baby's life was being measured - literally - in milligrams per decilitre.
And that number, that single serum bilirubin value, only became meaningful because of a reaction described over a century ago. In 1916, Abraham Albert Hijmans van den Bergh, a Dutch physician working in Utrecht, applied Ehrlich's diazo reaction to the measurement of bilirubin in serum. What he observed changed the way clinicians understand jaundice forever. He noticed something peculiar: in adult sera and in bile, bilirubin reacted rapidly with diazotized sulfanilic acid - a direct reaction. But in sera from jaundiced neonates, the reaction was slow, sluggish, requiring an accelerator like ethanol to proceed - an indirect reaction. Without knowing it at the time, van den Bergh had stumbled upon the biochemical distinction between conjugated and unconjugated bilirubin. Between water-soluble and lipid-soluble. Between bilirubin that can be excreted harmlessly in bile - and bilirubin that can cross the blood-brain barrier and destroy a developing brain.
This is not merely a chemistry test. It is a window into the liver. A triage tool. A prognostic instrument. In a neonate with pathological jaundice - like the one we just described - the Van den Bergh test tells us not just how much bilirubin is present, but what kind, and therefore what danger the baby is in.
Today, we examine this test in depth - its biochemical basis, its clinical interpretation, and why, over a century after its discovery, it remains the cornerstone of neonatal bilirubin assessment.
CONCLUSION
We began with a yellow baby. Twenty-two hours old. A TSB of 25 mg/dL dominated by unconjugated bilirubin - the indirect fraction - unbound to glucuronic acid, poorly soluble in water, tightly bound to albumin, and at those concentrations, hungry to diffuse across the blood-brain barrier and settle in the basal ganglia.
The Van den Bergh test gave us that information. It told us this was not obstructive jaundice - not a problem of excretion. It told us this was haemolytic and conjugation-deficient disease - a problem of overproduction and inadequate processing. In this baby's case, ABO incompatibility was driving red cell destruction, G6PD deficiency likely amplified it, and early sepsis compounded an already overwhelmed neonatal hepatic conjugating system - one which, even in a healthy term neonate, operates at only a fraction of adult UGT enzyme capacity for the first four weeks of life (Lippincott Biochemistry, 8th ed., p. 804).
Four exchange transfusions. Supplemental blood. Intensive phototherapy converting unconjugated bilirubin to water-soluble photoisomers excretable without conjugation. These interventions were not chosen blindly. They were guided - at every step - by the ability to measure, differentiate, and track bilirubin fractions through a colorimetric reaction first described in 1916.
The Van den Bergh test is deceptively simple: diazotized sulfanilic acid meets bilirubin, azodipyroles form, colour develops, absorbance is read. But the clinical intelligence encoded in that reaction - direct versus indirect, conjugated versus unconjugated, hepatocellular versus haemolytic versus obstructive - has informed every bedside jaundice decision made in the last hundred years.
That yellow baby we described at the start? He survived because someone acted fast, acted correctly, and acted with the right numbers. Clinicians who understand the biochemistry behind those numbers - who know why a direct reaction is fast and an indirect one is slow, who know what "25 mg/dL predominantly unconjugated" actually means physiologically - those are the clinicians who act correctly under pressure.
The Van den Bergh test is not history. It is every jaundiced neonate in your ward tonight.
Know it.
Source notes for your seminar: Van den Bergh reaction mechanism and neonatal bilirubin measurement are drawn from Lippincott Illustrated Reviews: Biochemistry, 8th ed., p. 803-805, and Tietz Textbook of Laboratory Medicine, 7th ed., p. 1971. Pathophysiology of neonatal jaundice and kernicterus from Robbins & Kumar Basic Pathology, pp. 619-620.
